What is Sirolimus (rapamycin)?
Blocks the signalling protein mTOR and thus the multiplication of immune cells. Approved in the EU since 2001 to prevent rejection after kidney transplantation and for sporadic lymphangioleiomyomatosis (LAM); promoted as an anti-ageing drug in the “longevity” scene.
How well studied is Sirolimus (rapamycin)?
Documented by registration trials for the approved indications. There is no evidence of life extension in humans: the placebo-controlled PEARL trial (114 participants, 48 weeks) missed its primary endpoint and showed only isolated changes in secondary outcomes; long-term benefit and safety in healthy people are unknown.
What side effects and risks does Sirolimus (rapamycin) have?
Immunosuppression with serious infections, higher risk of lymphoma and skin cancer (transplant doses), mouth ulcers, impaired wound healing, raised blood lipids and blood sugar (glucose intolerance) – working against the metabolic goals of GLP-1 therapy. Reported: testicular atrophy/infertility, menstrual disturbances; harmful to the unborn child. Very many interactions (CYP3A4, grapefruit); blood-level monitoring is normally needed.
Is Sirolimus (rapamycin) approved in Germany?
In short: yes. Approved in Germany/EU (Rapamune), prescription-only; use for “longevity” is off-label without proven benefit. Not on the WADA Prohibited List. Taking it without a prescription and medical monitoring – e.g. bought from “peptide shops” – is dangerous: unknown quality, no lab checks, no adjustment to blood pressure, kidney values or other medicines.
Sources
- Rapamune – EPAR (EMA)
- Rapamycin for longevity: the pros, the cons, and future perspectives (PMC)
- PEARL trial – Aging (Albany NY)
Note: We deliberately do not list any doses here. For approved medicines, your doctor sets the dose; for unapproved substances there is no reliable information.